{"transactions":[{"id":734386,"issuer":{"id":7767,"kind":"organization","name":"NeuroSense Therapeutics Ltd."},"owners":[{"id":37316,"kind":"person","name":"Ben-Noon Alon","position":1,"cik":"0001901198","reported_name":"Ben-Noon Alon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-17T20:30:02.000Z","date":"2026-06-16","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":0.8,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended."}],"balance_after":4534233,"source":{"system":"sec-edgar","filing":"0001213900-26-069663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026069663/ownership.xml","form_type":"4"}},{"id":734385,"issuer":{"id":7767,"kind":"organization","name":"NeuroSense Therapeutics Ltd."},"owners":[{"id":37315,"kind":"person","name":"Eisenberg Or","position":1,"cik":"0001721412","reported_name":"Eisenberg Or","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-17T20:30:02.000Z","date":"2026-06-16","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":0.8,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended."}],"balance_after":1504050,"source":{"system":"sec-edgar","filing":"0001213900-26-069662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026069662/ownership.xml","form_type":"4"}},{"id":823033,"issuer":{"id":7767,"kind":"organization","name":"NeuroSense Therapeutics Ltd."},"owners":[{"id":37315,"kind":"person","name":"Eisenberg Or","position":1,"cik":"0001721412","reported_name":"Eisenberg Or","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-04-01T20:26:11.000Z","date":"2026-03-26","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date."}],"balance_after":1254050,"source":{"system":"sec-edgar","filing":"0001213900-26-038545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026038545/ownership.xml","form_type":"4"}},{"id":825353,"issuer":{"id":7767,"kind":"organization","name":"NeuroSense Therapeutics Ltd."},"owners":[{"id":55345,"kind":"person","name":"Russek-Blum Niva","position":1,"cik":"0002124437","reported_name":"Russek-Blum Niva","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-30T21:32:00.000Z","date":"2026-03-26","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date."}],"balance_after":467953,"source":{"system":"sec-edgar","filing":"0001213900-26-036432","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026036432/ownership.xml","form_type":"4"}},{"id":825352,"issuer":{"id":7767,"kind":"organization","name":"NeuroSense Therapeutics Ltd."},"owners":[{"id":55344,"kind":"person","name":"Binder Hagit","position":1,"cik":"0002118272","reported_name":"Binder Hagit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Manager"}}],"security":"Ordinary Shares","published_at":"2026-03-30T12:49:28.000Z","date":"2026-03-26","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date."}],"balance_after":521806,"source":{"system":"sec-edgar","filing":"0001213900-26-036022","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026036022/ownership.xml","form_type":"4"}}]}